Key facts
- TargED Biopharmaceuticals’s last known valuation is $50.0M.
- It has raised $72.2M; the latest was Later Stage VC ($70.3M) in Dec 2025.
- Notable investors include European Innovation Council, Andera Partners, Utrecht Holdings, Rotrip Europe, BioGeneration Ventures — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for TargED Biopharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for TargED Biopharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TargED Biopharmaceuticals
Developer of biopharmaceutical drugs intended to serve doctors and healthcare professionals to improve the treatment of thrombosis. The company offers small antibody-based therapies that deliver enzymes directly to disease sites, enabling clients to accelerate treatment and enhance patient outcomes.
- Sector
- Healthcare
- HQ
- Utrecht, Netherlands
- Founded
- 2018
- Employees
- 33
- Ownership
- Privately Held (backing)
TargED Biopharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TargED Biopharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TargED Biopharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.